Wissenschaftliche Projekte, Studien, Veröffentlichungen, Fortbildungs-Veranstaltungen und Ausbildung gehören neben unserer Kerntätigkeit zu den Aufgaben eines Lehrkrankenhauses.
Eine Auflistung unserer aktuell durchgeführten Studien finden Sie hier:
Studiennummer: PRESTO
Studientitel: Organerhalt durch Immuntherapie auf Durvalumab-Basis in Kombination mit Chemotherapie und Bestrahlung als definitive Therapie für Adenokarzinome des Ösophagus im Frühstadium (cT1 und cT2N0) mit Indikation zur Radikaloperation: Eine prospektive, multizentrische Studie der FLOT-AIO Gastric Cancer Group
Verantwortlicher Arzt: Dr. Christian Müller
Status: geöffnet
Studiennummer: ACO/ARO/AIO 18.2
Studientitel: Preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure:
A randomized phase III trial of the German Rectal Cancer Study Group
Verantwortlicher Arzt: Dr. Christian Müller
Status: geöffnet
Studiennummer: Fire-8-Port (AIO-KRK/YMO-0519):
Studientitel: Prospective, randomized, open, multicenter Phase II trial to investigate the effcacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment of metastatic colorectal cancer.
Verantwortlicher Arzt: Dr. Christian Müller
Status: geöffnet
Studiennummer: Fire-9-Port (AIO-KRK-0418):
Studientitel: Post-resection/ablation chemotherapy in patients with metastatic colorectal cancer
Verantwortlicher Arzt: Dr. Christian Müller
Status: geöffnet
Studiennummer: Future-01
Studientitel: A phase II platform trial of futibatinib in combination with (chemo)immunotherapy in colorectal cancer and other solid tumor entities
Verantwortlicher Arzt: Dr. Christian Müller
Status: geöffnet
Studiennummer: Quintis
Studientitel: A Randomized Phase II Trial Evaluating Fruquintinib in Combination with Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer without Active Liver Metastases
Verantwortlicher Arzt: Dr. Christian Müller
Status: geöffnet
Studiennummer: CheckMate (CA209-274)
Studientitel: A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 274)
Verantwortlicher Arzt: Prof. Dr. Susanne Krege
Status: geöffnet
Studiennummer: Antelope (AIO-TRK-0122)
Studientitel: Atezolizumab/Carboplatin/nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in metastatic TTF-1 negative lung adenocarcinoma
Verantwortlicher Arzt: Dr. Sebastian Ertl
Status: geöffnet
Studiennummer: COCOON
Studientitel: A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic managemanet on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib
Verantwortlicher Arzt: Dr. Sebastian Ertl
Status: geöffnet
Studiennummer: GDFATHER-NSCLC-01
Studientitel: A Phase 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab versus Placebo, in Combination with Pembrolizumab, Pemetrexed, and Carboplatin, in First-Line Treatment of Participants with Metastatic Non-Squamous Non-Small Cell Lung Cancer
Verantwortlicher Arzt: Hr. Kostantinos Ferentinos
Status: geöffnet
Studiennummer: MK2870-023
Studientitel: A Phase 3 Study of Pembrolizumab in Combination With
Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer
Verantwortlicher Arzt: Dr. Sebastian Ertl
Status: geöffnet
Studiennummer: Marigold (Amgen 20210033)
Studientitel: A Randomized, Double-blind Study to Compare the Pharmacokinetics Between ABP 234 and Keytruda® (Pembrolizumab) in Subjects with Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy
Verantwortlicher Arzt: Dr. Sebastian Ertl
Status: geöffnet
Studiennummer: Krascendo-02
Studientitel: A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib versus Sotorasib or Adagrasib in Patients with Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
Verantwortlicher Arzt: Dr. Sebastian Ertl
Status: geöffnet
Studiennummer: MK2870-004
Studientitel: A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous. Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomic Alterations
Verantwortlicher Arzt: Dr. Sebastian Ertl
Status: geöffnet
Studiennummer: Eucalyptus (Amgen 20230127)
Studientitel: A Randomized, Double-blind Study to Compare the Pharmacokinetics Between ABP 234 and Keytruda® (Pembrolizumab) in Subjects with Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy
Verantwortlicher Arzt: Dr. Sebastian Ertl
Status: geöffnet
Studiennummer: R3767-ONC-2266
Studientitel: A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC
Verantwortlicher Arzt: Dr. Sebastian Ertl
Status: geöffnet
Studiennummer: Preserve-003
Studientitel: Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors
Verantwortlicher Arzt: Dr. Sebastian Ertl
Status: geöffnet
